Repros Therapeutics Inc.
RPRX
RPRX was delisted on the 31st of January, 2018.
43 hedge funds and large institutions have $9.45M invested in Repros Therapeutics Inc. in 2016 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 16 reducing their positions, and 15 closing their positions.
639% more call options, than puts
Call options by funds: $1.07M | Put options by funds: $145K
17% more capital invested
Capital invested by funds: $8.05M → $9.45M (+$1.4M)
19% less funds holding
Funds holding: 53 → 43 (-10)
63% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 16
67% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$737K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$335K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$256K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$165K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$65.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.18M |
| 2 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$970K |
| 3 |
GCM
Gruss Capital Management
New York
|
-$582K |
| 4 |
Millennium Management
New York
|
-$403K |
| 5 |
D.E. Shaw & Co
New York
|
-$232K |
RPRX Hedge Fund Activity: Q2 2016 in Review
43 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics Inc. (RPRX) for Q2 2016, worth a combined $9.45M — up 17% from $8.05M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of RPRX and 5 opened new positions — a net loss of 10 holders — while 16 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $737K. The largest seller was Fidelity Investments, cutting an estimated $1.18M.
- 43 institutional investors held Repros Therapeutics Inc. (RPRX) as of Q2 2016, down from 53 in Q1 2016.
- Funds reported $9.45M of Repros Therapeutics Inc. stock for Q2 2016, up 17% quarter-over-quarter.
- 5 funds opened new Repros Therapeutics Inc. positions in Q2 2016 and 15 closed out, a net change of -10 holders.
- The largest Repros Therapeutics Inc. buyer in Q2 2016 was Renaissance Technologies, an estimated $737K added.
- The largest Repros Therapeutics Inc. seller in Q2 2016 was Fidelity Investments, an estimated $1.18M sold.
Based on aggregated 13F filings for Q2 2016.